Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 35Prostate Cancer Metastatic 3Neoplasm Metastasis 3Prostate CA 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Oligometastatic Prostate Cancer 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-resistant Prostate Cancer 1Intraprostatic Prostate Cancer 1Genital Diseases, Male 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 57Carboplatin 34Paclitaxel 24Cyclophosphamide 23Capecitabine 18sacituzumab govitecan 16Specimen Handling 15130-nm albumin-bound paclitaxel 15toripalimab 11Drug Therapy 11Biopsy 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Taxes 9Epirubicin 9durvalumab 8Albumin-Bound Paclitaxel 8olaparib 7camrelizumab 7Gemcitabine 7Doxorubicin 7Docetaxel 7fludarabine 6famitinib 5Nivolumab 5Injections 5atezolizumab 4abemaciclib 4Trastuzumab 4Standard of Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Triple Negative Breast Neoplasms × Androgen Antagonists × Clear all
NCT07340541 2026-05-20

EVOLVE-BDT

UNC Lineberger Comprehensive Cancer Center

Phase 2 Recruiting
700 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡